{"title":"Urinoids — a new tool to study bladder cancer","authors":"Maria Chiara Masone","doi":"10.1038/s41585-024-00853-3","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":null,"pages":null},"PeriodicalIF":12.1000,"publicationDate":"2024-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Urology","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41585-024-00853-3","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
目前治疗膀胱癌的方法仅对少数患者有效，这表明需要根据个体肿瘤特征进行个性化治疗。发表在《英国癌症杂志》（British Journal of Cancer）上的一项新研究利用患者的尿液（尿样组织）无创建立了膀胱癌有机体。这些尿样再现了原始肿瘤的组织学特征和遗传特征。此外，尿组织对膀胱癌疗法的反应与其组织器官类似物相似。尽管存在一些局限性，例如培养物感染的几率增加，但尿液组织是一种快速、无创的获取患者器官组织的方法，证明了连续监测患者肿瘤特征和治疗反应的可行性。
期刊介绍：
Nature Reviews Urology is part of the Nature Reviews portfolio of journals.Nature Reviews' basic, translational and clinical content is written by internationally renowned basic and clinical academics and researchers. This journal targeted readers in the biological and medical sciences, from the postgraduate level upwards, aiming to be accessible to professionals in any biological or medical discipline.
The journal features authoritative In-depth Reviews providing up-to-date information on topics within a field's history and development. Perspectives, News & Views articles, and the Research Highlights section offer topical discussions and opinions, filtering primary research from various medical journals.
Covering a wide range of subjects, including andrology, urologic oncology, and imaging, Nature Reviews provides valuable insights for practitioners, researchers, and academics within urology and related fields.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
